Latest news for ViewRay (OTC:VRAYQ) Stock

ViewRay Inc is a radiation therapy and imaging technology company. It designs, manufactures, and markets radiation therapy systems that provide real-time imaging during radiation treatment. Its product portfolio encompasses The MRIdian linac system, The MRIdian system, the Monte Carlo treatment planning system, etc. The company holds the license for its combination of MRI and radiation therapy technologies. Geographically, it derives a majority of its revenue from the United States.

ViewRay Inc

Red Cat Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) reported second-quarter financial results for fiscal year 2025 after the bell on Monday. Here&#8217;s a <a href="https://www.benzinga.com/pressreleases/24/12/g42517778/red-cat-holdings-reports-financial-results-for-fiscal-second-quarter-2025-and-provides-corporate-u">rundown of the report</a>.
What Happened: Red Cat reported second-quarter revenue of $1.53 million, missing <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">analyst estimates</a> of $4.13 million. The drone technology company reported a second-quarter loss of 18 cents per share, missing analyst estimates for a loss of eight cents per share, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
&#8220;In the second half of 2024, our company decided to focus on the Black Widow, anticipating its success in the SRR final production contract,&#8221; said&nbsp;Jeff Thompson, CEO of Red Cat.&nbsp;
&#8220;We halted production of the Teal 2 to retool for the Black Widow, prioritizing long-term growth over short-term revenue. This strategy has proven successful, enabling us to meet the demands of the new Army contract and all other Black Widow sales and programs of record while managing critical technology integration through our Red Cat Futures Initiative partners. We are now well-positioned to fulfill these demands.&#8221;
Red Cat ended the quarter with $5.7 million in cash and accounts receivable. The company noted that it has closed on an additional $6 million in financing since the end of the quarter. 
Check This Out: <a href="https://www.benzinga.com/24/12/42507816/taiwan-semiconductor-ceo-highlights-ai-powered-drones-next-gen-robots-as-growth-drivers">Taiwan Semiconductor CEO Highlights AI-Powered Drones, Next-Gen Robots As Growth Drivers</a>
What&#8217;s Next: Red Cat expects full-year revenue for calendar year 2025 of $80 to $120 million. 
&#8220;We are also pleased to announce our partnership with Palantir. With Palantir&#8217;s Artificial Intelligence and visual navigation, we believe the Black Widow is one of the most capable drones ever fielded by the Department of Defense. This rucksack-portable drone, powered by Palantir&#8217;s software, will boost revenue per drone and increase gross margins,&#8221; Thompson said. 
Red Cat on Monday announced a <a href="https://www.benzinga.com/24/12/42513150/palantir-expands-ai-battlefield-solutions-with-red-cats-black-widow-drones">partnership</a> with Palantir Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) to integrate navigation software into its Black Widow drones. The collaboration is expected to help transform autonomous small unmanned aircraft systems operations for modern warfare.
Red Cat&#8217;s management team will further discuss highlights from the quarter on a call with analysts and investors at 4:30 p.m. ET.
RCAT Price Action: <a href="http://benzinga.com/quote/rcat" target="_blank" rel="noreferrer noopener">Red Cat Holdings shares</a> were down 13.88% in after-hours, trading at $9.04 at the time of publication Monday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: MAcroEcon via Shutterstock

Earnings

News

Guidance

After-Hours Center

Movers

Tech

PLTR

RCAT

Red Cat Holdings Q2 Earnings: Revenue, EPS Miss Estimates As Drone Company Prioritizes Long-Term Growth Over Short-Term Sales

Compass Minerals Sees Salt Sales Volumes For 2025 At The Midpoint Of Guidance Are Expected To Increase ~9% Over 2024, Assuming Average Sales-To-Commitment Ratios

The Securities and Exchange Commission approved spot Bitcoin ETFs in January 2024, which was a groundbreaking move at the time. The Bitcoin ETFs continue to see huge inflows months<a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42393396/record-week-bitcoin-etfs-net-25-billion-in-inflows-ethereum-etfs-took-in-12-billion"> after their launch.</a>
Here's a look back at the multi-year battle to get Bitcoin ETFs approved and how much investors could have made buying Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) when the first ETF was filed.
What Happened: Investors celebrated <a href="https://www.benzinga.com/markets/cryptocurrency/24/01/36514679/wall-street-enters-the-crypto-age-sec-issues-historic-approval-of-spot-bitcoin-etfs" target="_blank" rel="noopener">the approval of </a>Bitcoin ETFs earlier this year, with the SEC approving the first applications for many ETFs.
The approval opened the door for more investors, including institutional investors and retirement accounts, to get exposure to the leading cryptocurrency through the launched ETFs.
Months after launch, Bitcoin ETFs are seeing strong inflows, which could be thanks in part to new optimism for the cryptocurrency sector after the 2024 election. Bitcoin hit new all-time highs<a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41778425/bitcoins-all-time-high-a-groundbreaking-milestone-and-strong-post-election-rally-coming-ex"> after the 2024 election</a> and recently surpassed the $100,000 milestone<a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42336184/exclusive-bitcoin-crossing-100000-is-a-defining-moment-experts-say"> for the first time.</a>
Last week, Bitcoin ETFs saw net inflows of $2.5 billion, bringing the year-to-date total to more than $36 billion.
Here's a look at the top Bitcoin ETFs today by assets under management, as reported by <a href="https://etfdb.com/themes/bitcoin-etfs/">ETFdb</a>.
<ul>
<li>iShares Bitcoin Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>): $53.9 billion</li>
<li>Grayscale Bitcoin Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBTC#NYSE">GBTC</a>): $21.5 billion</li>
<li>Fidelity Wise Origin Bitcoin Fund (BATS:<a class="ticker" href="https://www.benzinga.com/stock/FBTC#BATS">FBTC</a>): $21.0 billion</li>
<li>ARK 21Shares Bitcoin ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKB#BATS">ARKB</a>): $4.9 billion</li>
<li>Bitwise Bitcoin ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BITB#NYSE">BITB</a>): $4.1 billion</li>
<li>Grayscale Bitcoin Mini Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTC#NYSE">BTC</a>): $4.0 billion</li>
<li>ProShares Bitcoin ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BITO#NYSE">BITO</a>): $2.6 billion</li>
<li>Volatility Shares Trust 2x Bitcoin Strategy ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/BITX#BATS">BITX</a>): $2.0 billion</li>
</ul>
Before the approved Bitcoin ETFs were filed, or the Grayscale Bitcoin Trust was launched in September 2013, there was an S-1 filed for a Bitcoin ETF with the SEC.
On July 1, 2013,&nbsp;Gemini&nbsp;founders&nbsp;Cameron and Tyler Winklevoss&nbsp;filed the Winklevoss Bitcoin Trust as a planned Bitcoin ETF. The Winklevoss twins saw their initial filing and a second attempt rejected in 2018.
Cameron Winklevoss commented on the status of Bitcoin ETFs on the 10-year anniversary of the filing, which happened several months ago, <a href="https://twitter.com/cameron/status/1675302282915610624" target="_blank" rel="noreferrer noopener">saying</a>: "The SEC&#8217;s refusal to approve these products for a decade has been a complete and utter disaster for U.S. investors and demonstrates how the SEC is a failed regulator."
Winklevoss accused the SEC of helping to push investors into&nbsp;FTX, which&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/22/11/29681030/ftx-files-for-chapter-11-bankruptcy" target="_blank" rel="noreferrer noopener">eventually went bankrupt</a>&nbsp;and was &#8220;one of the largest financial frauds in modern history.&#8221;
The Gemini co-founder wished luck to all the companies fighting to bring Bitcoin ETFs to market.
In January, ahead of the Bitcoin ETFs' approval, Cameron Winklevoss took to Twitter to share the optimism of Bitcoin ETFs.
&#8220;Today is 3,845 days in the making. Happy Bitcoin ETF Approval Day!&#8221; Winklevoss&nbsp;<a href="https://twitter.com/cameron/status/1745122379594871057" target="_blank" rel="noreferrer noopener">tweeted</a>.
Here&#8217;s a look back at investing in Bitcoin when the Winklevoss brothers filed for the first ETF launch.
Read Also: <a href="https://www.benzinga.com/general/education/24/12/42345466/if-you-invested-1000-in-bitcoin-when-peter-schiff-said-btc-would-never-hit-100k-heres-how-much-youd-have-now">If You Invested $1,000 In Bitcoin When Peter Schiff Said BTC Would Never Hit $100K, Here&#8217;s How Much You&#8217;d Have Now</a>
Investing $1,000 in BTC: Bitcoin hit all-time highs of nearly $69,000 in November 2021 before breaking out to new highs this year, and has traded above $10,000 for many years. It may be surprising to some that Bitcoin traded below $100 during parts of 2012 and that year marked the first time the leading cryptocurrency hit the $1,000 level.
On July 1, 2013, Bitcoin traded for around $90.80. A $1,000 investment in Bitcoin could have purchased 11.0132 BTC at the time.
Based on a price of $106,478.56 at the time of publication, the $1,000 investment would be worth $1,172,669.68 today. This represents a hypothetical return of over 117,000% over the last 11 years.
Over the past decade, Bitcoin has delivered stronger returns than leading stocks and has outpaced the overall stock market.
For Comparison
<ul>
<li>A $1,000 investment in the&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which tracks the S&amp;P 500, would be worth $3,736.80 today. This represents a gain of 273.7% over the last 11 years.</li>
<li>A $1,000 investment in&nbsp;Tesla Inc&nbsp;over the same time period would be worth $58,480.93 today. This represents a hypothetical return of 5,748.1% over the last 11 years.</li>
<li>A $1,000 investment in&nbsp;Apple Inc&nbsp;over the same time period would be worth $17,035.49 today. This represents a hypothetical return of 1,603.5% over the last 11 years.</li>
</ul>
While Bitcoin may not beat the market and leading stocks by the same amounts over the next decade, there is increased optimism that the new White House administration could continue to send the leading cryptocurrency higher.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42399353/heres-how-much-100-in-bitcoin-could-be-worth-in-2030-if-cathie-woods-price-target-is-reached">Here&#8217;s How Much $100 In Bitcoin Could Be Worth In 2030 If Cathie Wood&#8217;s Price Target Is Reached</a></li>
</ul>
This article was previously published by Benzinga and has been updated.
Image created using artificial intelligence via Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Education

$BTC

ARK 21Shares Bitcoin ETF ARK 21Shares Bitcoin ETF

ARKB

Bitwise Bitcoin ETF Common Shares of Beneficial Interest

BITB

BITO

BITX

Fidelity Wise Origin Bitcoin Fund Fidelity Wise Origin Bitcoin Fund

FBTC

GBTC

IBIT

If You Invested $1,000 In Bitcoin When The First Bitcoin ETF Was Filed, Here's How Much You'd Have Today

Electrovaya Inc. ("Electrovaya" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVA#NASDAQ">ELVA</a>, TSX:<a class="ticker" href="https://www.benzinga.com/stock/ELVA#TSX">ELVA</a>), a leading lithium-ion battery technology and manufacturing company, is pleased to announce that the Company is commencing an underwritten public offering (the "Offering") of its common shares (the "Common Shares"). All of the shares are being offered by the Company.
The shares will be offered in the United States pursuant to a shelf registration statement (including a prospectus supplement thereto) previously filed with and declared effective by the Securities and Exchange Commission (the "SEC") on September 25, 2024 in accordance with the Multijurisdictional Disclosure System established between Canada and the United States, and will be qualified for distribution in the provinces and territories of Canada by way of a prospectus supplement to the Company's base shelf prospectus dated September 17, 2024, provided that no securities will be sold in the Province of Québec.
Roth Capital Partners, Raymond James Ltd. and Craig-Hallum Capital Group LLC are acting as the co-lead book-running managers for the proposed Offering.

Offerings

ELVA

TSX:ELVA

Electrovaya Announces Proposed Public Offering Of Common Shares And Files Preliminary Prospectus Supplement; No Size Or Amount Disclosed

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) has outperformed the market over the past 10 years by 5.78% on an annualized basis producing an average annual return of 17.1%. Currently, Insmed has a market capitalization of $13.19 billion. 
Buying $1000 In INSM: If an investor had bought $1000 of INSM stock 10 years ago, it would be worth $4,519.09 today based on a price of $73.75 for INSM at the time of writing.
<h3>Insmed's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734385511_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

INSM

If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today

Netcapital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCPL#NASDAQ">NCPL</a>) reported quarterly losses of $(2.34) per share which missed the analyst consensus estimate of $(1.29) by 81.4 percent. This is a 192.86 percent decrease over earnings of $2.52 per share from the same period last year. The company reported quarterly sales of $170.53 thousand which missed the analyst consensus estimate of $1.05 million by 83.84 percent. This is a 91.65 percent decrease over sales of $2.04 million the same period last year.

Earnings Misses

NCPL

Netcapital Q2 EPS $(2.34) Misses $(1.29) Estimate, Sales $170.53K Miss $1.05M Estimate

The special dividend will be payable no later than January 31, 2025, or earlier, if the proposed merger with Blue Owl Capital closes before that date.&nbsp;

Dividends

OBDC

OBDE

Blue Owl Capital Corporation III Declares Special Dividend Of $0.52 Per Share

Management

Ryder System Announced Cristina Gallo-Aquino as CFO, effective January 1, 2025

NAAS

NaaS Technology Inc Files For Offering Up To 4.8M American Depositary Shares

Buybacks

EBAY

On December 12, 2024, eBay Board Authorizes Incremental $3B Under Stock Repurchase Program, In Addition To Remaining Amounts Previously Authorized - Filing

BD (Becton, Dickinson and Company) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>), a leading global medical technology company, today issued the following statement:
BD has reached an agreement with the U.S. Securities and Exchange Commission (SEC) to resolve the previously disclosed investigation related to prior public disclosures and SEC reporting regarding the BD Alaris&#x2122; System, which was acquired by BD from CareFusion in 2015 and is part of the BD Medication Management Solutions business.
The SEC Order, the findings of which BD neither admits nor denies, relate to matters concerning BD Alaris that occurred more than four years ago. As part of the settlement, BD has agreed to pay $175 million to the SEC, an amount that was reserved and disclosed in the company's fiscal year 2024 Form 10-K and was contemplated in BD's fiscal year 2025 cash flow plan. No financial restatements are required as a result of the settlement, and the settlement amount does not impact BD's investments in innovation or its previously disclosed capital allocation strategy. BD is not updating its fiscal 2025 guidance as a result of the settlement. The company believes that settling with the SEC is the right course of action to fully resolve this matter and move forward.
The BD Alaris&#x2122; System is safe and effective and is a critical part of health care in the United States. The system has been used for many years to safely deliver IV therapies to patients, including throughout the COVID-19 pandemic. The updated BD Alaris&#x2122; System received 510(k) clearance from the U.S. Food and Drug Administration in July 2023, and the company continues to update its Alaris fleet.
BD has implemented a number of improvements to its operational and governance processes and related disclosure practices. BD is committed to operating with integrity and the highest ethical standards to produce high-quality, safe and effective products and serve as a trusted partner for its customers and their patients.

Legal

BD Resolves Previously Disclosed SEC Investigation Related To Prior Public Disclosures And SEC Reporting Regarding The BD Alaris System; BD Has Agreed To Pay $175M To The SEC; BD Is Not Updating Its Fiscal 2025 Guidance As A Result Of The Settlement

The earnings results for Compass Minerals Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMP#NYSE">CMP</a>) for Q4 were made public on Monday, December 16, 2024 at 04:35 PM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
Compass Minerals Intl missed estimated earnings by -71.0%, reporting an EPS of $-0.77 versus an estimate of $-0.45.
Revenue was down $24.80 million from the same period last year.
<h3>Overview of Past Earnings</h3>
The company missed on EPS by $0.27 in the previous quarter, leading to a 3.0% drop share price change the next day.
Here's a look at Compass Minerals Intl's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.74</td>
<td>0.27</td>
<td>0.26</td>
<td>-0.04</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.01</td>
<td>1.49</td>
<td>0.05</td>
<td>-0.06</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>197.77M</td>
<td>406.92M</td>
<td>357.90M</td>
<td>231.26M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>202.90M</td>
<td>364.00M</td>
<td>341.70M</td>
<td>233.60M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Compass Minerals Intl <a href="https://www.benzinga.com/quote/CMP/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Compass Minerals Intl: Q4 Earnings Insights

Due to the continued unpredictability of timing related to the closing of new contracts, the Company has not provided more specific guidance related to the timing of bookings.

STRM

Streamline Health Reiterates $15.5M Implemented SaaS ARR Adjusted EBITDA Breakeven Run Rate Expectation; Accelerates Expectation For Achievement The Goal To H1 Of FY25

Compass Minerals Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMP#NYSE">CMP</a>) reported quarterly losses of $(0.77) per share which missed the analyst consensus estimate of $(0.45) by 71.11 percent. This is a 1183.33 percent decrease over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $208.80 million which missed the analyst consensus estimate of $209.00 million by 0.10 percent. This is a 10.62 percent decrease over sales of $233.60 million the same period last year.

Compass Minerals Intl Q4 Adj $(0.77) Misses $(0.45) Estimate, Sales $208.80M Miss $209.00M Estimate

Ryder System Announced The Appointment Of John J. Diez To President And COO, Effective January 1, 2025

Streamline Health Q3 EPS $(0.61) Up From $(3.15) YoY, Sales $4.42M Down From $6.13M YoY

CENT

Central Garden & Pet Increases Authorization Under Stock Repurchase Program; To Purchase Up To An Additional $100M Of Issued And Outstanding Shares

Fiscal Year 2025 Guidance
Amentum affirms its fiscal year 2025 guidance originally presented at Capital Markets Day on August 13, 2024 and provides Adjusted Diluted Earnings Per Share (EPS) guidance.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">(in millions, except per share data)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="7" rowspan="1">Fiscal Year 2025 Guidance</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenues</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$13,800</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$14,200</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA1</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$1,060</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$1,100</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted Diluted EPS1</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$2.00</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$2.20</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Free Cash Flow1</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$475</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$525</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="9" rowspan="1">1 – Represents a Non-GAAP financial measure - see the related explanations included elsewhere in this release. Amentum does not provide a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP measures due to the inherent difficulty in forecasting and quantifying certain significant items. These items are uncertain, depend on various factors and could have a material impact on GAAP reported results for the relevant period.</td>
</tr>
</tbody>
</table>
</figure>

AMTM

Amentum Holdings Sees FY25 EPS $2.00-$2.20; Revenue $13.8B-$14.2B

Biotech

Events

General

TNYA

Tenaya Therapeutics To Announce Initial Data From MyPEAK-1 Phase 1b/2 Clinical Trial Of TN-201 Gene Therapy For MYBPC3-Associated Hypertrophic Cardiomyopathy On Dec. 17, 2024

Amentum Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMTM#NYSE">AMTM</a>) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.26 by 7.69 percent. The company reported $2.21 billion in sales this quarter. This is a 3.51 percent increase over sales of $2.14 billion the same period last year.

Comments

ViewRay

News

Latest news for ViewRay (OTC:VRAYQ) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga